Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade

Executive Summary

Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.

You may also be interested in...



Alnylam Switches Attention To Access After Onpattro EU Okay

European approval is in the bag for Onpattro for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis but in a week where ICER has criticized the price of the RNAi drug in the US, Alnylam now has to navigate reimbursement talks on this side of the Atlantic.

Alnylam's Onpattro Carries Narrower hATTR Indication Without Cardiac Data

US FDA still appears to be open, if not optimistic, about path towards broader label for patisiran, the first-of-its-kind targeted RNA-based therapy. 

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel